ReviewMicroorganisms2021
Immunoglobulin A, an Active Liaison for Host-Microbiota Homeostasis.
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Probiotic supplementation is associated with higher faecal secretory IgA (sIgA) in healthy full-term infants: a systematic review and meta-analysis.Pediatric research · 2026Pooled it
- Pooled it
- Analysis of gut microbiota variations in patients with Henoch-Schönlein purpura: a comprehensive systematic review.International urology and nephrology · 2025Pooled it
- Altered SIgA-targeting of gut microbiota is associated with long-term dysbiosis in pediatric solid organ transplant recipients.Gut microbes · 2026Article
- N-Carbamylglutamate Promotes Growth and Immunity in Danzhou Chickens via Gut Microbiota-Metabolite Interactions Involving Sphingolipid and mTOR Pathways.Microorganisms · 2026Article
- The Role of Novel Immunomodulators in the Treatment of Autoimmune Hepatitis.Journal of clinical and translational hepatology · 2025Review
- Exploring and evaluating microbiome resilience in the gut.FEMS microbiology ecology · 2025Review
- Bioactive nanomotor enabling efficient intestinal barrier penetration for colorectal cancer therapy.Nature communications · 2025Article
- Intestinal immunoglobulins under microbial dysbiosis: implications in opioid-induced microbial dysbiosis.Frontiers in microbiology · 2025Review
- Digestive dynamics: Unveiling interplay between the gut microbiota and the liver in macronutrient metabolism and hepatic metabolic health.Physiological reports · 2024Review
- The interaction between autophagy, Helicobacter pylori, and gut microbiota in gastric carcinogenesis.Trends in microbiology · 2023Review
- The Underappreciated Role of Secretory IgA in IBD.Inflammatory bowel diseases · 2023Article
- Microbial Reprogramming in Obsessive-Compulsive Disorders: A Review of Gut-Brain Communication and Emerging Evidence.International journal of molecular sciences · 2023Review
- Crosstalk between Gut Microbiota and Host Immunity: Impact on Inflammation and Immunotherapy.Biomedicines · 2023Review
- Microbiota of the gastrointestinal tract: Friend or foe?World journal of gastroenterology · 2023Review
- Increasing taxonomic and functional characterization of host-microbiome interactions by DIA-PASEF metaproteomics.Frontiers in microbiology · 2023Article
- Six Decades of History of Hypertension Research at the University of Toledo: Highlighting Pioneering Contributions in Biochemistry, Genetics, and Host-Microbiota Interactions.Current hypertension reports · 2022Review
- Selective IgA Deficiency in Spontaneously Hypertensive Rats With Gut Dysbiosis.Hypertension (Dallas, Tex. : 1979) · 2022Article
- Selective IgA Deficiency and Allergy: A Fresh Look to an Old Story.Medicina (Kaunas, Lithuania) · 2022Review
- Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Mucosal surfaces in the gastrointestinal tract are continually exposed to native, commensal antigens and susceptible to foreign, infectious antigens. Immunoglobulin A (IgA) provides dual humoral responses that create a symbiotic environment for the resident gut microbiota and prevent the invasion of enteric pathogens. This review features recent immunological and microbial studies that elucidate the underlying IgA and microbiota-dependent mechanisms for mutualism at physiological conditions. IgA derailment and concurrent microbiota instability in pathological diseases are also discussed in detail. Highlights of this review underscore that the source of IgA and its structural form can dictate microbiota reactivity to sustain a diverse niche where both host and bacteria benefit. Other important studies emphasize IgA insufficiency can result in the bloom of opportunistic pathogens that encroach the intestinal epithelia and disseminate into circulation. The continual growth of knowledge in these subjects can lead to the development of therapeutics targeting IgA and/or the microbiota to treat life threatening diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.